Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1958–1961. doi: 10.1128/aac.37.9.1958

Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes.

G Raponi 1, M C Ghezzi 1, C Mancini 1, F Filadoro 1
PMCID: PMC188099  PMID: 8239612

Abstract

The release of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) by human monocytes stimulated with whole heat-killed Candida albicans CA3 (a clinical isolate) and CA2 (a germ tube-negative mutant) either treated or not treated with amphotericin B was investigated. The optimal release of the cytokines was observed at 24 h of incubation of the yeasts with the monocytes for both TNF-alpha and IL-6. The levels ranged from 10,500 to 19,000 U/ml for TNF-alpha and from 350 to 460 pg/ml for IL-6. Germ tube-negative mutant CA2 induced the release of TNF-alpha at levels significantly (P < 0.05) lower than those induced by clinical isolate CA3, while no major differences were observed between the two strains with regard to their capacity to induce the release of IL-6. In all instances, preincubation of the yeasts with a sublethal concentration of amphotericin significantly reduced cytokine production. These results suggest that drug-induced alterations of fungal outer structures may affect the interactions between the yeasts and the monocytes, resulting in a reduced level of secretion of cytokines.

Full text

PDF
1958

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Bassam T., Poulain D., Giummelly P., Lematre J., Bonaly R. Chemical and antigenic alterations of Candida albicans cell walls related to the action of amphotericin B sub-inhibitory doses. J Antimicrob Chemother. 1985 Mar;15(3):263–269. doi: 10.1093/jac/15.3.263. [DOI] [PubMed] [Google Scholar]
  2. Bistoni F., Vecchiarelli A., Cenci E., Puccetti P., Marconi P., Cassone A. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun. 1986 Feb;51(2):668–674. doi: 10.1128/iai.51.2.668-674.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blasi E., Pitzurra L., Puliti M., Bartoli A., Bistoni F. Candida albicans hyphal form enhances tumor necrosis factor mRNA levels and protein secretion in murine ANA-1 macrophages. Cell Immunol. 1992 Jun;142(1):137–144. doi: 10.1016/0008-8749(92)90275-t. [DOI] [PubMed] [Google Scholar]
  4. Blasi E., Pitzurra L., Puliti M., Lanfrancone L., Bistoni F. Early differential molecular response of a macrophage cell line to yeast and hyphal forms of Candida albicans. Infect Immun. 1992 Mar;60(3):832–837. doi: 10.1128/iai.60.3.832-837.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brouqui P., Dupont H. T., Drancourt M., Bourgeade A., Raoult D. Spotless boutonneuse fever. Clin Infect Dis. 1992 Jan;14(1):114–116. doi: 10.1093/clinids/14.1.114. [DOI] [PubMed] [Google Scholar]
  6. Brummer E., Morrison C. J., Stevens D. A. Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun. 1985 Sep;49(3):724–730. doi: 10.1128/iai.49.3.724-730.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  8. Cassone A. Cell wall of Candida albicans: its functions and its impact on the host. Curr Top Med Mycol. 1989;3:248–314. doi: 10.1007/978-1-4612-3624-5_10. [DOI] [PubMed] [Google Scholar]
  9. Chia J. K., McManus E. J. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother. 1990 May;34(5):906–908. doi: 10.1128/aac.34.5.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cho S. Y., Choi H. Y. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol. 1979 Oct;72(4):617–621. doi: 10.1093/ajcp/72.4.617. [DOI] [PubMed] [Google Scholar]
  11. Damas P., Ledoux D., Nys M., Vrindts Y., De Groote D., Franchimont P., Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992 Apr;215(4):356–362. doi: 10.1097/00000658-199204000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Diamond R. D., Haudenschild C. C. Monocyte-mediated serum-independent damage to hyphal and pseudohyphal forms of Candida albicans in vitro. J Clin Invest. 1981 Jan;67(1):173–182. doi: 10.1172/JCI110010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Djeu J. Y., Blanchard D. K., Richards A. L., Friedman H. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol. 1988 Dec 1;141(11):4047–4052. [PubMed] [Google Scholar]
  14. Evron R. In vitro phagocytosis of Candida albicans by peritoneal mouse macrophages. Infect Immun. 1980 Jun;28(3):963–971. doi: 10.1128/iai.28.3.963-971.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jeremias J., Kalo-Klein A., Witkin S. S. Individual differences in tumour necrosis factor and interleukin-1 production induced by viable and heat-killed Candida albicans. J Med Vet Mycol. 1991;29(3):157–163. doi: 10.1080/02681219180000261. [DOI] [PubMed] [Google Scholar]
  16. Johnson E. M., Warnock D. W., Richardson M. D., Douglas C. J. In-vitro effect of itraconazole, ketoconazole and amphotericin B on the phagocytic and candidacidal function of human neutrophils. J Antimicrob Chemother. 1986 Jul;18(1):83–91. doi: 10.1093/jac/18.1.83. [DOI] [PubMed] [Google Scholar]
  17. Klein R. S., Harris C. A., Small C. B., Moll B., Lesser M., Friedland G. H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. doi: 10.1056/NEJM198408093110602. [DOI] [PubMed] [Google Scholar]
  18. Ruff M. R., Gifford G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980 Oct;125(4):1671–1677. [PubMed] [Google Scholar]
  19. Schuit K. E. Phagocytosis and intracellular killing of pathogenic yeasts by human monocytes and neutrophils. Infect Immun. 1979 Jun;24(3):932–938. doi: 10.1128/iai.24.3.932-938.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Steinshamn S., Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun. 1992 Oct;60(10):4003–4008. doi: 10.1128/iai.60.10.4003-4008.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Van 't Wout J. W., Meynaar I., Linde I., Poell R., Mattie H., Van Furth R. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J Antimicrob Chemother. 1990 May;25(5):803–811. doi: 10.1093/jac/25.5.803. [DOI] [PubMed] [Google Scholar]
  22. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253–278. doi: 10.1146/annurev.iy.08.040190.001345. [DOI] [PubMed] [Google Scholar]
  23. Van t Wout J. W., Mattie H., van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother. 1989 Feb;33(2):147–151. doi: 10.1128/aac.33.2.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vecchiarelli A., Puliti M., Torosantucci A., Cassone A., Bistoni F. In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of Candida albicans cell wall. Cell Immunol. 1991 Apr 15;134(1):65–76. doi: 10.1016/0008-8749(91)90331-5. [DOI] [PubMed] [Google Scholar]
  25. de Brabander M., Aerts F., van Cutsem J., van den Bossche H., Borgers M. The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans. Sabouraudia. 1980 Sep;18(3):197–210. doi: 10.1080/00362178085380351. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES